Viscosupplementation Market Size Will Projected to Reach ~US$4.8 Billion by 2027 | Exclusive Report by TMR

The global viscosupplementation market is anticipated to achieve a value of approximately US$4.8 billion by the end of 2027, reflecting steady growth in the demand for non-surgical treatments for osteoarthritis (OA). Starting from an estimated US$2.8 billion in 2019, this trajectory suggests a compound annual growth rate (CAGR) of around 6.2% over the eight-year period. This expansion is driven by an aging population, increasing prevalence of joint disorders, and advancements in hyaluronic acid-based therapies. As healthcare shifts toward minimally invasive solutions, the viscosupplementation market is poised to play a key role in orthopedic care through 2027.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10232

Understanding Viscosupplementation

Viscosupplementation involves injecting hyaluronic acid (HA) into joints, typically the knee, to restore synovial fluid viscosity, reduce pain, and improve mobility in patients with osteoarthritis. Available in single-injection, three-injection, and five-injection regimens, it serves as an alternative to painkillers or surgery for those with mild to moderate OA. The market's projected rise to ~US$4.8 billion by 2027 highlights its growing acceptance as a safe, effective treatment, addressing a widespread condition that affects millions globally.

The assumed 6.2% CAGR reflects a consistent growth pattern, balancing established use with emerging innovations. As a bridge between conservative management and invasive procedures, viscosupplementation meets a critical need in joint health.

Key Drivers of Market Growth

Several factors are driving the viscosupplementation market toward its ~US$4.8 billion valuation by 2027. First, the aging global population is a primary catalyst. With the number of individuals over 60 projected to rise significantly by 2030, osteoarthritis prevalence is increasing, particularly in weight-bearing joints like knees and hips. This demographic shift fuels demand for treatments that delay surgery and enhance quality of life.

Second, rising awareness and preference for minimally invasive options are boosting growth. Patients and physicians are opting for viscosupplementation over chronic NSAID use or joint replacement due to its lower risk profile and shorter recovery time. Clinical evidence supporting HA's efficacy in pain relief and function improvement further supports its adoption, aligning with the market's upward trajectory.

Third, product innovations are expanding the market's scope. Newer single-injection formulations, such as high-molecular-weight HA, offer convenience and sustained benefits, while advancements in cross-linked HA improve durability within the joint. These developments enhance patient compliance and satisfaction, contributing to the estimated growth to US$4.8 billion.

Leading Players:

Sanofi
Anika Therapeutics, Inc.
Seikagaku Corporation
Zimmer Biomet
Ferring B.V.
LG Chem
Chugai Pharmaceutical Co., Ltd,
Bioventus, Inc.

Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10232

Market Segmentation and Regional Insights

The market segments by product type, application, and geography. Single-injection viscosupplements are gaining popularity for their ease of use, though multi-injection regimens retain a strong share due to cost-effectiveness in some markets. Knee OA dominates applications, reflecting its high prevalence, with emerging use in hips and shoulders. Distribution channels include hospitals, orthopedic clinics, and pharmacies, with clinics leading due to specialized care.

Regionally, North America held a significant share in 2019, driven by high OA rates, advanced healthcare infrastructure, and reimbursement support in the United States. Europe followed, with strong markets in Germany and France, supported by aging populations. The Asia-Pacific region, however, was poised for rapid growth through 2027, fueled by rising healthcare access, increasing arthritis awareness, and economic growth in China and India.

Challenges and Opportunities

The market faced challenges during this period. Reimbursement inconsistencies-particularly in the U.S., where some insurers questioned HA's long-term efficacy-limited access for certain patients. Competition from alternatives like platelet-rich plasma (PRP) and stem cell therapies also posed threats, offering different mechanisms for joint relief. Additionally, high costs of premium single-injection products could deter adoption in cost-sensitive regions.

These challenges, however, opened opportunities. Companies improving clinical evidence through large-scale trials could strengthen reimbursement cases and boost confidence, supporting the push to US$4.8 billion. Developing affordable, high-quality generics or expanding into emerging markets with tailored pricing could broaden access. Innovations like combination therapies (e.g., HA with anti-inflammatories) also held potential to exceed projections.

The Road to 2027

By 2027, the global viscosupplementation market reached its estimated ~US$4.8 billion, reflecting eight years of steady growth from an assumed US$2.8 billion in 2019 at a 6.2% CAGR. This achievement was driven by demographic trends, patient preferences, and product advancements. As the period concluded, the market's foundation suggested continued relevance, with potential for further growth as OA management evolves.

In conclusion, the viscosupplementation market demonstrated solid growth from 2019 to 2027. Rising to ~US$4.8 billion, it addressed a pressing need for non-surgical OA relief. Stakeholders-from manufacturers to healthcare providers-played a vital role in this success, ensuring that viscosupplementation remained a key, accessible option in orthopedic care through 2027 and beyond.

Explore Latest Research Reports by Transparency Market Research:

Pharma 4.0 Market: https://www.pharmiweb.com/press-release/2025-03-18/pharma-40-market-size-will-estimated-to-grow-at-a-cagr-of-177-by-2035-driven-by-digital-transformation-in-drug-manufacturing-exclusive-report-by

Dialysis Equipment Market: https://www.pharmiweb.com/press-release/2025-03-18/dialysis-equipment-market-poised-to-surpass-us-252-bn-by-2035-amidst-rising-ckd-cases-and-technological-advancements-tmr-insights

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.